Insulin and dexamethasone dynamically regulate adipocyte 11beta-hydroxysteroid dehydrogenase type 1.

Area of Science:

• Endocrinology
• Molecular Biology
• Metabolic Syndrome Research

Background:

• 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) in adipocytes amplifies local glucocorticoids, contributing to obesity and metabolic syndrome.
• The precise regulation of adipocyte 11beta-HSD1 by key hormones like insulin and glucocorticoids remains incompletely understood.

Purpose of the Study:

• To investigate the effects of insulin and glucocorticoids on 11beta-HSD1 activity and expression in 3T3-L1 adipocytes.
• To elucidate the underlying molecular mechanisms of these hormonal effects.
• To validate in vitro findings in an in vivo setting.

Main Methods:

• Utilized 3T3-L1 adipocytes for in vitro studies.
• Assessed 11beta-HSD1 activity and expression following insulin and dexamethasone treatment.
• Employed specific inhibitors for signaling pathways (p38 MAPK, ERK, PI3K) and glucocorticoid receptor antagonist (RU486).
• Examined mRNA half-life and conducted in vivo studies in rat white adipose tissue.

Main Results:

• Insulin stimulated 11beta-HSD1 activity and expression post-transcriptionally, involving p38 MAPK activation and increased mRNA half-life.
• Dexamethasone inhibited 11beta-HSD1 activity and expression via a glucocorticoid receptor-mediated transcriptional mechanism.
• In vivo, both insulin and dexamethasone augmented 11beta-HSD1 activity and expression in rat adipose tissue, contrasting with in vitro results for dexamethasone.

Conclusions:

• Insulin stimulates adipocyte 11beta-HSD1 through p38 MAPK and post-transcriptional regulation.
• Dexamethasone inhibits adipocyte 11beta-HSD1 via transcriptional regulation mediated by the glucocorticoid receptor.
• Significant differences exist in dexamethasone's regulation of adipocyte 11beta-HSD1 between in vitro and in vivo models.